An Early Access Program for pharmaceutical grade L-Glutamine (oral powder) for the treatment of Sickle Cell Disease patients that have exhausted other remaining treatment options

Trial Profile

An Early Access Program for pharmaceutical grade L-Glutamine (oral powder) for the treatment of Sickle Cell Disease patients that have exhausted other remaining treatment options

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs Glutamine (Primary)
  • Indications Sickle cell anaemia
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 10 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top